Company Filing History:
Years Active: 2022
Title: Innovations of Qiuxia Wang in Avian Influenza Research
Introduction
Qiuxia Wang is a notable inventor based in Yangzhou, China. He has made significant contributions to the field of avian influenza research, particularly through his innovative patent related to the H7N9 subtype virus. His work is crucial in addressing the challenges posed by avian influenza in poultry and its potential impact on public health.
Latest Patents
Qiuxia Wang holds a patent for a recombinant H7N9 subtype avian influenza virus, inactivated marked vaccine, and its preparation method. This invention provides a recombinant H7N9 subtype avian influenza virus, utilizing strain JD/17 as the parent virus. The patent details a method where a peptide sequence in the HA protein of strain JD/17 is replaced with a peptide sequence from the HA protein of H3 subtype. The strain JD/17 has a preservation number of CCTCC No. V201862. The results indicate that the rescued virus maintains similar biological characteristics to the parent virus, such as high HA titers and EID50. Chickens immunized with the marked inactivated and emulsified vaccine produce a high level of antibody, which can be distinguished from antibodies produced by chickens naturally infected with the H7N9 subtype avian influenza virus.
Career Highlights
Qiuxia Wang is affiliated with Yangzhou University, where he conducts his research and development activities. His work has been instrumental in advancing the understanding and management of avian influenza viruses. His innovative approach to vaccine development showcases his commitment to improving animal health and preventing disease outbreaks.
Collaborations
Qiuxia Wang collaborates with esteemed colleagues, including Daxin Peng and Sujuan Chen. Their combined expertise enhances the research efforts and contributes to the success of their projects.
Conclusion
Qiuxia Wang's contributions to avian influenza research through his innovative patent highlight the importance of scientific advancements in public health. His work not only addresses immediate challenges but also paves the way for future developments in vaccine technology.